혈액 여과 및 정화 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Blood Filtration And Purification Market Growth & Trends:

The global blood filtration and purification market size is anticipated to reach USD 5.63 billion by 2030 and is projected to grow at a CAGR of 7.34% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of blood-borne diseases, growing geriatric population, rising awareness of blood purification therapies have fueled the market growth.

The blood filtration & purification industry in clinical diagnostics experienced a major surge during the COVID-19 pandemic, driven by the urgent need for effective treatment solutions for critically ill patients. Among the most vital tools during this period were advanced blood purification kits, which played a critical role in managing severe inflammatory responses, organ failure, and complications associated with the virus.

At the forefront of this innovation was OXIRIS, a multifunctional blood purification filter set-the only one available in the U.S. capable of performing Continuous Renal Replacement Therapy (CRRT) while simultaneously removing cytokines and inflammatory mediators from the blood. During the height of the pandemic, OXIRIS became a key therapeutic solution for managing critically ill COVID-19 patients who were experiencing cytokine storms, sepsis, and acute kidney injury. By efficiently removing inflammatory substances, the kit helped stabilize patients, reduce intensive care burden, and improve survival outcomes.

Thermo Scientific's GeneJET Whole Blood Genomic DNA Purification Mini Kit stands out for its rapid, spin-column-based silica membrane technology. This kit streamlines DNA extraction from whole blood, eliminating the need for hazardous phenol-chloroform extraction or time-consuming alcohol precipitation. With a standard protocol that takes under 20 minutes post-lysis, it delivers high molecular weight DNA (>30 kb), ready for downstream applications like PCR, Southern blotting, and enzymatic assays. The kit's simplicity and reliability make it a preferred choice for laboratories looking to scale genomic diagnostics with speed and safety.

SpiNXT Blood DNA Extraction Kit is another innovative solution, designed for use with whole blood, plasma, serum, lymphocytes, and buffy coat. Combining silica-binding chemistry with a mini spin-column format, it ensures high-yield, high-purity DNA isolations across a range of blood-derived sample types. With no need for organic solvents or complicated equipment, the SpiNXT kit enables fast processing and compatibility with a wide array of clinical genetic assays.

Meanwhile, the sbeadex Blood DNA Purification Kit brings magnetic bead-based technology into focus. Designed for sample volumes up to 200 µL, the kit supports high-throughput automation workflows and is fully compatible with popular platforms like Thermo Fisher's KingFisher(TM) system. Its water-based wash buffers help eliminate carryover of organic solvents and PCR inhibitors, ensuring clean DNA suitable for sensitive applications such as qPCR, NGS, Sanger sequencing, and genetic disorder screening.

The pandemic highlighted the critical role of blood purification kits in managing high-risk patients. As healthcare systems adapted to the challenges of COVID-19, these kits became indispensable tools not only for diagnostic support but also for therapeutic intervention. Their impact has extended beyond the pandemic, with continued use in managing sepsis, kidney injury, and other inflammation-driven conditions.

The COVID-19 crisis accelerated the adoption of blood filtration and purification kits such as OXIRIS, CytoSorb, AMBER, and Hemoclear, setting a new benchmark for integrated clinical diagnostics and critical care. These innovations remain central to modern ICU practice, ensuring that the lessons learned during the pandemic translate into stronger, more responsive healthcare systems going forward.

Blood Filtration And Purification Market Report Highlights:

• The filtration kits & reagents segment led the market with the largest revenue share of 35.97% in 2024. This segment is expected to see rapid expansion due to its critical role in ensuring the safety and efficacy of blood transfusions, therapeutic treatments, and medical research. A key driving factor is the technological advancements in filtration materials, and a growing global demand for high-quality blood products further contributes to the dominance of filtration kits and reagents in the market.
• Based on application, the infectious disease diagnostics segment accounted for the largest market revenue share in 2024, due to the growing global prevalence of infectious diseases and the critical need for accurate, rapid diagnostics. The genetic/molecular diagnostics segment is expected to grow at the fastest CAGR over the forecast period, due to the increasing demand for precise, personalized healthcare solutions.
• Based on end use, the clinical diagnostics laboratories segment accounted for the largest market revenue share in 2024, due to their essential role in disease detection and monitoring. These laboratories rely on advanced filtration technologies to obtain high-quality, contaminant-free blood samples for accurate testing, especially in infectious disease diagnostics, genetic testing, and oncology. With the rise of personalized medicine and early disease detection, clinical diagnostic labs are adopting cutting-edge filtration technologies, driving both the size and growth of this market segment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Filtration & Purification Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD)
    • 3.2.1.2. Increasing prevalence of bloodborne diseases
    • 3.2.1.3. Advancements in hemodialysis and renal care
    • 3.2.1.4. Rising Demand for safe blood transfusions
    • 3.2.1.5. Technological advancements in filtration and purification systems
    • 3.2.1.6. Growing use of liquid biopsy for cancer diagnostics
    • 3.2.1.7. Regulatory push for improved blood safety standards
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High equipment costs
    • 3.2.2.2. Lack of awareness and skilled professionals
• 3.3. Blood Filtration & Purification Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Blood Filtration & Purification Market: Product Estimates & Trend Analysis

• 4.1. Blood Filtration & Purification Market: Product Dashboard
• 4.2. Global Blood Filtration & Purification Market Product Movement Analysis
• 4.3. Global Blood Filtration & Purification Market by Product Outlook
• 4.4. Filtration kits and Reagents
  • 4.4.1. Filtration kits and Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Membranes, Filters and Consumables
  • 4.5.1. Membranes, Filters and Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Sample preparation systems
  • 4.6.1. Sample preparation systems market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Specialty assays and columns
  • 4.7.1. Specialty assays and columns market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Blood Filtration & Purification Market: Application Estimates & Trend Analysis

• 5.1. Blood Filtration & Purification Market: Application Dashboard
• 5.2. Global Blood Filtration & Purification Market Application Movement Analysis
• 5.3. Global Blood Filtration & Purification Market by Application Outlook
• 5.4. Infectious Disease Diagnostics
  • 5.4.1. Infectious Disease Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Toxicology and Immunodiagnostics
  • 5.5.1. Toxicology and Immunodiagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Cancer Diagnostics
  • 5.6.1. Cancer Diagnostics market estimates and forecasts, 2018 to 2030, (USD Million)
• 5.7. Genetic/Molecular Diagnostics
  • 5.7.1. Genetic/Molecular Diagnostics market estimates and forecasts, 2018 to 2030, (USD Million)
• 5.8. Others (Metabolic, Rare Disease Panels
  • 5.8.1. Genetic/Molecular Diagnostics market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Blood Filtration & Purification Market: End-use Estimates & Trend Analysis

• 6.1. Blood Filtration & Purification Market: End-use Dashboard
• 6.2. Global Blood Filtration & Purification Market End-use Movement Analysis
• 6.3. Global Blood Filtration & Purification Market by End-use Outlook
• 6.4. Clinical Diagnostics
  • 6.4.1. Clinical Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Research and Academic Institutes
  • 6.6.1. Research and Academic Institutes market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Blood Filtration & Purification Market: Regional Estimates & Trend Analysis by Product, Application and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Thermo Fischer Scientific
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. MilliporeSigma
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Roche Lifescience
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sigma Aldrich
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Avantor.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Takara Bio
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. MP Biomedicals
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. QIAGEN N.V
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. HiMedia
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Biotage
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives